Loading clinical trials...
Loading clinical trials...
A Randomized, Open-label Study of Prophylactic Administration of PEGASYS Plus Ribavirin After Liver Transplantation on Hepatitis C Recurrence in Patients With Hepatitis C
Conditions
Interventions
peginterferon alfa-2a [Pegasys]
Copegus
Locations
28
United States
Birmingham, Alabama, United States
Phoenix, Arizona, United States
Los Angeles, California, United States
San Francisco, California, United States
San Francisco, California, United States
Aurora, Colorado, United States
Start Date
October 1, 2004
Primary Completion Date
October 1, 2008
Completion Date
October 1, 2008
Last Updated
March 29, 2018
NCT05870969
NCT03200379
NCT03155906
NCT03987503
NCT05397067
NCT04382404
Lead Sponsor
Hoffmann-La Roche
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions